Latest intangible assets for BMYMP: $17B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), BMYMP shows a intangible assets of $17B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BMYMP's intangible assets is now $17B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb Company PFD CONV 2 is outperforming or lagging.
Tracking BMYMP's intangible assets over time shows whether Bristol-Myers Squibb Company PFD CONV 2 is scaling, shrinking, or reshaping that part of the business. The current reading is $17B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this intangible assets page, Stockcircle has Bristol-Myers Squibb Company PFD CONV 2's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $17B) with ownership activity and broader fundamentals.
Bristol-Myers Squibb Company PFD CONV 2's intangible assets is $17B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.